Académique Documents
Professionnel Documents
Culture Documents
Background
Symptomatic remission, including negative and cognitive symptoms, remain
suboptimal for many patients with psychosis.
Taurine is an inhibitory neuromodulatory amino-acid in the CNS and
activates GABA- and glycine-insensitive chloride channel and inhibits the
NMDA receptor. Taurine also functions as a neuroprotective agent and has a
role in neural development and neurogenesis.
Aim
To determine the efficacy of adjunctive taurine in improving
symptomatology and cognition among patients with a DSM-IV firstepisode
psychotic disorder.
Table 2. Demographic and clinical characteristics of the two treatment groups at baseline
Taurine
(n=47)
11 (28.2)
-2
Age, mean SD
21.42.3
21.32.3
-3
12.12.2
12.62.3
-4
14 (29.8)
14 (35.9)
-5
27 (57.4)
26 (66.7)
-6
100.310.1
99.712.0
-7
34 (72.3)
26 (66.7)
7 (14.9)
11 (28.2)
Design
7 (14.9)
6 (15.4)
Schizoaffective disorder
3 (6.4)
4 (10.3)
1 (2.1)
0 (0.0)
Delusional disorder
2 (4.3)
1 (2.6)
Sample
13 (27.7)
5 (12.8)
Outcome Variables
Assessment Instrument
Overall
symptomatology
Cognition
-9
12-weeks
*Not significant
2
1
0
Taurine
Placebo
6-weeks
12-weeks
p=.026
-0.5
-1.0
Discussion
-2.0
Adjunctive taurine is safe and appears to have clinical benefit in firstepisode psychosis.
While adjunctive taurine did not improve cognition, it improved total
symptomatology, psychotic symptoms, depression and functioning in
patients with first-episode psychosis.
The use of taurine warrants further investigation in larger randomised
studies, particularly early in the course of psychosis.
-2.5
Taurine
Placebo
6-weeks
12-weeks
p=.047
-0.5
-1.0
Assessed for
eligibility
N=252
Excluded
N=41
Declined
N=90
-1.5
-2.0
Psychotic Symptoms
Negative Symptoms
Depression
Clinical improvement
Functioning
Consented,
randomised
N=121
-2.5
Taurine
Placebo
Allocated to Taurine
N=61
Allocated to Placebo
N=60
p=.04
5
4
Received Taurine
N=52
Received Placebo
N=45
At least 1 follow-up;
Included in analysis
N=47
At least 1 follow-up;
Included in analysis
N=39
Contact
Patrick McGorry
pat.mcgorry@orygen.org.au
3
2
1
0
35 Poplar Road
Parkville VIC 3052
1300 679 436
Taurine
Placebo
14234_ORYGEN_STUDIO_2016
Funding: This trial was supported by a Stanley Medical Research Institute grant 06T.
Clinical Trials Registration: This trial is registered with http://www.clinicaltrials.gov
trial number NCT00420823.
6-weeks
Placebo
-1.5
Secondary outcomes
Results
Taurine
Co-primary outcomes
p=.004
-8
Schizophreniform disorder
12-weeks
320
21 (53.8)
Exclusion criteria
6-weeks
-1
15 (31.9)
17 (36.2)
Demographic Characteristics
Female, n (%)
Dose of antipsychotic
(CPZ equivalence), median
Diagnosis, n (%)
Schizophrenia
Method
Placebo
(n=39)